Literature DB >> 9013943

T cell adhesion to P-selectin induces tyrosine phosphorylation of pp125 focal adhesion kinase and other substrates.

H Haller1, U Kunzendorf, K Sacherer, C Lindschau, G Walz, A Distler, F C Luft.   

Abstract

Lymphocyte binding to endothelial surface adhesion molecules is an important early step in inflammation, which is mediated initially by P-selectin and E-selectin. We tested the hypothesis that lymphocyte binding to the selectin adhesion molecules induces intracellular signaling by tyrosine phosphorylation. We used an adhesion assay, which relied on cell binding to chimeric proteins consisting of the extracellular domains for P-selectin and E-selectin. Tyrosine phosphorylation was determined using anti-phosphotyrosine Abs by confocal microscopy and Western blot. Binding to P-selectin induced a significant increase in anti-phosphotyrosine immunoreactivity. The P-selectin effect was time dependent with an early response after 10 min and a maximum effect at 30 min. Western blot showed a time-dependent phosphorylation of two distinct 68- and 125-kDa proteins. These proteins were pp125 focal adhesion kinase (FAK) and paxillin, as shown by immunoprecipitation and colocalization. Phosphorylation of pp125 FAK was time dependent reaching a maximum after 30 min. Incubation with the tyrosine kinase inhibitor genistein, and, to a lesser extent, with the protein kinase C inhibitor staurosporine, resulted in decreased pp125 FAK phosphorylation. Our results are the first to demonstrate that lymphocyte binding to P-selectin induces tyrosine phosphorylation of distinct proteins. Thus, lymphocyte activation may occur already at the initial contact with surface adhesion molecules.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9013943

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Focal adhesion kinases: interest in immunoendocrinology, developmental biology, and cancer.

Authors:  H J Martens; V Geenen
Journal:  Endocrine       Date:  2000-12       Impact factor: 3.633

2.  The mechanism of mononuclear cell infiltration in oral lichen planus: the role of cytokines released from keratinocytes.

Authors:  T Yamamoto; T Nakane; T Osaki
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.317

Review 3.  Perspectives series: cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment.

Authors:  R P McEver; R D Cummings
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

Review 4.  Current concepts of platelet activation: possibilities for therapeutic modulation of heterotypic vs. homotypic aggregation.

Authors:  Gabriella Passacquale; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

5.  P-selectin activates integrin-mediated colon carcinoma cell adhesion to fibronectin.

Authors:  Merit E Reyes-Reyes; Margaret D George; John D Roberts; Steven K Akiyama
Journal:  Exp Cell Res       Date:  2006-09-16       Impact factor: 3.905

Review 6.  Ischemia/Reperfusion.

Authors:  Theodore Kalogeris; Christopher P Baines; Maike Krenz; Ronald J Korthuis
Journal:  Compr Physiol       Date:  2016-12-06       Impact factor: 9.090

Review 7.  Cell biology of ischemia/reperfusion injury.

Authors:  Theodore Kalogeris; Christopher P Baines; Maike Krenz; Ronald J Korthuis
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

8.  SLIC-1/sorting nexin 20: a novel sorting nexin that directs subcellular distribution of PSGL-1.

Authors:  Ulrich Y Schaff; Heather H Shih; Meike Lorenz; Dianne Sako; Ron Kriz; Kim Milarski; Brian Bates; Boris Tchernychev; Gray D Shaw; Scott I Simon
Journal:  Eur J Immunol       Date:  2008-02       Impact factor: 5.532

9.  Spleen tyrosine kinase Syk is critical for sustained leukocyte adhesion during inflammation in vivo.

Authors:  David Frommhold; Ingrid Mannigel; Jürgen Schymeinsky; Attila Mocsai; Johannes Poeschl; Barbara Walzog; Markus Sperandio
Journal:  BMC Immunol       Date:  2007-11-28       Impact factor: 3.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.